CeriBell Inc (CBLL) (Q3 2026) Earnings Call Highlights: Record Hospital Additions
CeriBell Inc (CBLL) reported Q3 2026 revenue of $29.3M, up 30% YoY, with 35 new hospitals added. Gross margin improved to 90%, but net loss widened to $21.4M. Full-year guidance raised to $115-$117M. Delirium monitoring pilot showed clinical impact, but no material revenue contribution yet. Operating expenses rose 36% YoY. CEO Jane Chao and CFO Scott Blomberg discussed growth strategies and 2027 outlook.
How this was made
The 30-second read
Why it matters
Traders can reassess near-term growth quality (utilization and account penetration) against cost pressure (OpEx and adjusted EBITDA loss) and guidance conservatism (bottom-end raise only, no material new-product contribution).
Market read
A company-specific earnings/guidance update with quantified operating metrics and a new-product pilot narrative that may affect expectations for 2027 growth and profitability trajectory.
What to watch
The potential $2.9M deferred legal fees tied to the IPR proceeding and the lack of quantified delirium utilization impact could be underweighted versus the headline revenue and hospital metrics.
Background
The piece summarizes CeriBell’s Q3 2026 earnings call, emphasizing hospital account growth, headband utilization records, and early clinical validation of its delirium monitoring solution.
Ticker impact
CeriBell reported Q3 results with revenue up ~30% YoY to $29.3M, record 35 new hospitals, and raised full-year 2026 guidance only at the bottom end to $115-$117M.
Likely choppy reaction, with upside support from record hospital additions and 90% gross margin, offset by loss expansion and limited guidance raise.
The article contains multiple same-call quantitative positives (revenue growth, hospital adds, gross margin, utilization records) and negatives (net loss and OpEx growth, adjusted EBITDA loss, modest guidance raise, legal-fee overhang), which typically drives a balanced but volatile post-earnings repricing.
Market effects
Reinforces investor focus on utilization-driven growth and gross margin expansion in hospital monitoring/medical device software models.
None indicated.
None indicated.
Counterpoint
The record hospital additions and utilization gains may not translate into durable revenue acceleration because delirium contribution is not yet reflected in guidance and rollout timing is still uncertain.
Key entities
- companyCeriBell Inc
Reported Q3 2026 earnings call highlights including revenue growth, record hospital additions, gross margin improvement, and guidance details for full-year 2026.
- executiveJane Chao
CEO who discussed delirium pilot impact, utilization drivers, and product rollout timing.
- executiveScott Blomberg
CFO who discussed guidance, expense drivers, and VA account rollout expectations.